Skip to main content

Table 5 Incidence of TIV reactogenicity events from Day 0† to Day 3 in the Safety Set

From: Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons

Symptom

TIV

N = 3783 n (%)

Placebo

N = 3828 n (%)

P-value¶

At least 1 vaccine reactogenicity event

2487 (66)

1675 (44)

<0.0001

Fever‡

96 (3)

55 (1)

0.0005

Injection site pain/soreness

1933 (51)

530 (14)

<0.0001

Injection site redness

475 (13)

234 (6)

<0.0001

Injection site swelling

418 (11)

109 (3)

<0.0001

Myalgia and/or arthralgia

692 (18)

389 (10)

<0.0001

Headache

683 (18)

716 (19)

0.5491

Tiredness

761 (20)

678 (18)

0.0049

Chills

158 (4)

136 (4)

0.1526

Malaise

338 (9)

236 (6)

<0.0001

Red eyes

250 (7)

231 (6)

0.2772

Swelling of the face

51 (1)

37 (<1)

0.1327

Cough

286 (8)

250 (7)

0.0719

Chest tightness or difficulty in breathing

128 (3)

107 (3)

0.1274

Sore throat, hoarseness or pain on swallowing

324 (9)

344 (9)

0.5689

  1. †>30 minutes post-vaccination
  2. ¶Fisher's Exact test (p < 0.05 considered significant)
  3. ‡Temperature ≥37.5°C/99.5°F